Gene therapy for gastric cancer: is it promising?
Gastric cancer is one of the most common tumors worldwide. The therapeutic outcome of conventional therapies is inefficient. Thus, new therapeutic strategies are urgently needed. Gene therapy is a promising molecular alternative in the treatment of gastric cancer, including the replacement of defective tumor suppressor genes, the inactivation of oncogenes, the introduction of suicide genes, genetic immunotherapy, anti-angiogenetic gene therapy, and virotherapy. Improved molecular biological techniques and a better understanding of gastric carcinogenesis have allowed us to validate a variety of genes as molecular targets for gene therapy. This review provides an update of the new developments in cancer gene therapy, new principles, techniques, strategies and vector systems, and shows how they may be applied in the treatment of gastric cancer.
Department of Gastroenterology/Infectious Diseases/Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany. andreas.sutter@schering.de
Andreas P
AP
Sutter
Henry
H
Fechner
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D020868:Gene Silencing; D041722:Genes, Transgenic, Suicide; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D013274:Stomach Neoplasms / Q000235:genetics / Q000628:therapy; D014780:Viruses
D020533:Angiogenesis Inhibitors